Substitution, Shortage, and Clinical Risk: Managing Medication Continuity When the Usual Product Is Unavailable

Medication shortages and “backorder” events increasingly force frontline teams to use alternatives: different strengths, formulations, brands, or routes. In community settings, these changes are high-risk because the person’s routine, understanding, and self-management may be disrupted. Providers working within medication, equipment and supply chain continuity must therefore treat substitution as a clinical safety process, aligned to continuity of operations planning for HCBS and LTSS, not a procurement workaround.

When substitution is unmanaged, harm often appears as non-adherence (“they refused”), deterioration (“they’re unstable again”), or behavioral escalation (“they’re more anxious”). In reality, the change itself—appearance, taste, dosing schedule, delivery device—may be the trigger. A defensible approach defines who can authorize substitution, how the person’s consent is supported, what monitoring is required, and how learning is captured for future events.

Why substitution is different from “continuity”

Continuity planning often focuses on getting the medication. Substitution planning focuses on preserving safety, therapeutic effect, and the person’s ability to manage. It requires coordination across the prescriber, pharmacy, care team, and—critically—the person and their family supports. It also intersects with rights: individuals must not be pressured into unwanted changes without adequate explanation and alternatives.

Operational example 1: Shortage-triggered clinical huddle with decision authority

What happens in day-to-day delivery
When a shortage is identified (pharmacy notification, failed refill, backorder alert), the provider triggers a same-day “clinical huddle” workflow. A designated clinical lead (RN/PharmD/medical director depending on model) reviews: the medication’s purpose, current dose, last fill date, adherence history, and any recent instability. The team confirms available options: alternative brand, different strength requiring dose calculation, therapeutic equivalent, or temporary bridging plan. The huddle documents who authorized the decision, what was decided, and what monitoring will occur. If the person self-manages, staff schedule a targeted support contact to review changes and confirm understanding.

Why the practice exists (failure mode it addresses)
This prevents unapproved substitutions being made ad hoc by frontline staff or families. It also prevents dosing errors when strengths or formulations change, and it ensures the change is clinically coherent rather than “whatever is available.”

What goes wrong if it is absent
Staff may administer the wrong dose, duplicate therapy, or unintentionally change the route (e.g., tablet vs. liquid) without considering swallow safety or absorption differences. People may disengage or refuse due to confusion, leading to deterioration and avoidable utilization.

What observable outcome it produces
Providers see fewer medication incidents linked to shortages, clearer decision trails for audits, and improved timeliness of stabilization after substitution events.

Operational example 2: Consent and comprehension support for medication changes

What happens in day-to-day delivery
Providers use a structured “medication change conversation” process when a substitution occurs. Staff explain: what changed, why it changed, what remains the same (purpose), how to take it, and what to watch for. Communication is adapted to the person’s needs (plain language, translated materials, visual prompts, or involvement of a trusted supporter). Where the person uses adherence aids (blister packs, pill organizers), staff ensure packaging reflects the new product and that administration prompts are updated. The team records consent (or best-interest decision-making where legally applicable) and documents any concerns, including sensory aversion, anxiety about change, or prior history of non-adherence after substitutions.

Why the practice exists (failure mode it addresses)
Many substitution failures are not “clinical” failures but comprehension failures: the person does not recognize the medication, thinks it is wrong, or cannot use a new device. This practice prevents avoidable refusal and protects rights by ensuring the person is genuinely informed.

What goes wrong if it is absent
People may stop taking the medication, take it incorrectly, or become distressed. Staff may respond with pressure or restrictive practices (“you have to take it”), creating safeguarding risk and complaints.

What observable outcome it produces
Providers can evidence improved adherence after substitutions, fewer behavior incidents tied to medication change distress, and stronger safeguarding defensibility through documented consent support.

Operational example 3: Post-substitution monitoring and “early warning” escalation

What happens in day-to-day delivery
After substitution, the provider implements a time-limited monitoring plan tailored to risk. For high-risk meds (anticoagulants, insulin, antipsychotics, seizure meds), staff increase check-ins for a defined period (e.g., 72 hours to two weeks depending on medication), monitor for side effects or symptom recurrence, and ensure rapid access to prescriber review if needed. The monitoring plan includes clear escalation triggers: missed doses, new confusion, falls, blood sugar instability, breakthrough seizures, or significant mood/behavior change. Findings are documented and reviewed by the clinical lead, and any adverse outcomes are fed into incident management and future continuity planning.

Why the practice exists (failure mode it addresses)
This prevents delayed recognition of destabilization. Substitutions may be pharmacologically equivalent but still produce different effects due to formulation, absorption, device use, or routine disruption.

What goes wrong if it is absent
Deterioration may be noticed only when a crisis occurs (ED visit, hospitalization, safeguarding incident). Providers then struggle to evidence proactive management or explain why early signs were missed.

What observable outcome it produces
Providers can show earlier interventions, reduced crisis escalation, and measurable stability indicators (fewer unplanned contacts, fewer incidents, improved adherence tracking) following substitution events.

Explicit regulator and funder expectations

Regulators and Medicaid funders expect medication management to remain safe and person-centered during shortages. In practice, oversight bodies look for (1) clear clinical authorization pathways for substitutions, and (2) evidence that the person’s rights and consent were protected, with reasonable adjustments for comprehension. During audits or investigations, commissioners expect documentation that the provider recognized shortage risk, acted promptly, and monitored outcomes rather than assuming equivalence alone ensures safety.

Where shortages contribute to avoidable utilization, funders may require corrective actions such as strengthened pharmacy relationships, alternative sourcing agreements, or enhanced monitoring protocols for high-risk individuals.

Building a substitution-ready continuity system

Providers can reduce future risk by maintaining a “shortage playbook” for high-risk medications: preferred alternatives, prescriber contacts, packaging considerations, consent support templates, and monitoring checklists. The strongest systems treat substitution events as learning opportunities, using after-action reviews to update protocols, staff competency, and supplier arrangements.